Call Now
May 20, 2024
Amgen, one of the world’s leading biotechnology companies, is known for pioneering biologics for serious diseases. It’s leveraging tech like advanced data analytics and AI paired with de-identified human data to transform drug discovery and development. Microsoft Copilot for Microsoft 365 is an important part of this approach, boosting productivity and fostering a more inclusive global workforce. This strategic use of AI not only has the potential to speed up drug development but also supports advancements in Amgen’s business processes.
Services
Industry
Size
Country
As a biopharmaceutical powerhouse, Amgen stands out in its industry as one of the first to pioneer the use of biologics to treat some of the world’s toughest diseases. Founded in 1980, the company helped establish the biotechnology industry and remains on the cutting edge of innovation, using technology and human genetic data to push beyond what’s known today. Its commitment to research and development has yielded a robust pipeline focused on cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases.
Amgen was one of the earliest in the industry to develop the machinery and processes to make complex biologic medicines at scale. “We have a proud heritage of developing biologics for some of the world’s toughest diseases, and we believe our manufacturing capability helps differentiate us,” says Mike Zahigian, Senior Vice President and Chief Information Officer at Amgen. “Today, we are accelerating our science with technology and data to help target diseases with high unmet need,” he adds.
Realizing AI has the potential to accelerate innovation and empower employees by significantly enhancing productivity and efficiency, Amgen rolled out Microsoft Copilot for Microsoft 365 and scaled from 300 users in the Early Access Program to now include 20,000 employees worldwide with access to Copilot. “When we had the opportunity with Microsoft [and Copilot], we put our hands up because we thought the hinge moment is here,” says Amgen. “And if you believe that, then you want to start developing an educated, highly sophisticated workforce that’s able to use this new technology.”
